The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1171
December 8, 2003
View Complete Issue         Table of Contents 2019 
Efalizumab (Raptiva) for Treatment of Psoriasis
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Efalizumab (Raptiva) for Treatment of Psoriasis
December 8, 2003 (Issue: 1171)
Efalizumab (Raptiva - Genentech/XOMA), a humanized monoclonal antibody that inhibits T-cell activation, has been approved by the FDA for treatment of adults with moderate to severe chronic plaque psoriasis.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Efalizumab (Raptiva) for Treatment of Psoriasis
Article code: 1171a
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.